A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG, Amgen (Neupogen)

Final Accrual

20

Trial Chairperson

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Clinical Trial Registration

Related Post

SOCRATES HCC trial - all Australian sites open
5 March, 2025

All Australian sites open for SOCRATES HCC trial

5 March 2025: TRIAL UPDATE We’re excited to have

TROG trial in focus DCIS
4 March, 2025

TRIAL IN FOCUS: DCIS delivers valuable evidence

4 March 2025: A decade on from the last